Be in the know. 17 key reads for Thursday…

  1. 13 Stock Ideas From Top Value Managers (Barron’s)
  2. Gilead’s Remdesivir Is a Rare Example of Foresight in This Pandemic (Bloomberg)
  3. What’s Good for Banks Isn’t Necessarily Good for Bankers (Wall Street Journal)
  4. Deals Aren’t Dead. Here Are 12 Stocks That Could Become Buyout Targets (Barron’s)
  5. Green Shoots for the Economy and 5 More Things to Know (Barron’s)
  6. As Stock Buybacks Disappear, Dividends Stand to Gain (Barron’s)
  7. As States Reopen, Home Purchase Applications Rise for the Fourth Week in a Row (Barron’s)
  8. Mnuchin Seeks to Assuage Investors After Powell’s Gloomy Outlook (Bloomberg)
  9. Trump Says He Disagrees With Fauci’s Concerns Over Reopening (Bloomberg)
  10. Wisconsin Supreme Court strikes down state’s ‘stay-at-home’ order (CNBC)
  11. A London-based trading house bought 250,000 barrels of oil during the historic plunge below $0, and likely made a fortune. (Business Insider)
  12. U.S. weekly jobless benefits to stay elevated as coronavirus layoffs widen (Reuters)
  13. AbbVie’s Potential Is ‘Underappreciated,’ Says Morgan Stanley Analyst (Benzinga)
  14. The Swedish Model Trades More Disease for Less Economic Damage (Bloomberg)
  15. Oil Price Crash Could Hurt Trump in Texas, Help in Pennsylvania (Bloomberg)
  16. New York and New Jersey Start to Reopen Their Economies (Wall Street Journal)
  17. Fed TALF Revision Could Help Clear CLO Logjam (Wall Street Journal)